AGENCY POLICIES

IMPORTANT:
Read the orders & instructions provided in the home by the dispensing pharmacy!
Orders & pharmacy instructions/protocols supersede Agency policy.
 

Section 7: Risk Management

​​

• 7A.13 Patient Abuse, Neglect or Exploitation

• 7B.2 Standard Precautions

• 7B.4 Personal Protective Equipment

• 7B.6 Hand Hygiene

• 7B.8 Bag Technique & Equipment Maintenance

• 7B.10 Sharps Injury Protection Plan

  • 7B.10a Sharps Injury Report​

• 7B.22 Tuberculosis Testing & Screening

• 7B.28 Influenza Vaccine Program

  • 7B.28a Encouraging Influenza Vaccine (Handout)

• 7B.32 Coronavirus: Nursing Staff

  • 7B.32a COVID Screening Questionnaire (Form)

  • 7B.32b Coronavirus Education (Handout)​​​​​​​

​

Section 8A: Clinical Practices

​​

• 8A.0 Storage & Disposal of Medications, Supplies & Waste

• 8A.2 Medication Orders and Administration

• 8A.4 Medications Pre and Post Infusion Therapy

• 8A.6 Medication Reactions and Side Effects

• 8A.8 First Dose Protocols & Administration

• 8A.10 Emergency Medications & Interventions

• 8A.12 Aseptic Technique

• 8A.14 Obtaining Labs & Communicating Results

• 8A.20 Start of Care Education Practices

  • 8A.20a Start of Care: Infusion Therapy Brochure (Handout)​

• 8A.22 Enteral Education Practices

• 8A.24 Wound Care Education Practices
   

Section 8B: Pumps & Drug Administration

​

• 8B.0 Administering IV Medications: Dispensing & Delivery

• 8B.6 Manipulation of Vials & Ampules

• 8B.10 Medication Administration Teaching Practices

• 8B.12 Chemotherapy Takedown Education Practices

• 8B.14 Hydration Therapy Education Practices

• 8B.16 Controlled Substance

• 8B.20 Intravenous Immune Globulin (IVIg)

• 8B.22 Subcutaneous Immune Globulin (SCIg)

• 8B.24 Remicade & Biosimilar

• 8B.26 C1 Esterase Inhibitor Products for HAE

• 8B.28 Coagulant Blood Products for Bleeding Disorders

• 8B.30 Subcutaneous Injections

• 8B.32 Intramuscular Injections

• 8B.40 Entyvio (Vedolizumab) Administration

• 8B.42 Actemra (Tocilizumab) Administration

• 8B.50 Alpha-1 Proteinase Inhibitors

• 8B.60 Enzyme Replacement Therapy

• 8B.65 Vyjuvek Preparation & Administration

• 8B.70 Rystiggo Administration

​

Section 8C: Vascular Access Devices

​

• 8C.0 Blood Draw Practices & Procedures

• 8C.2 PICC & Central Line Dressing Change

• 8C.3 CathFlo Activase

• 8C.4 Removal of Non-Tunneled Catheters

  • 8C.4a PICC Removal: Post-Care Instructions (Handout)​

• 8C.6 Accessing & Discontinuing Implantable Ports

• 8C.8 Peripheral Access & Removal

• 8C.10 VAD Flushing & Maintenance

• 8C.18 Non-Dialysis AV Fistula Graft Access & Care

​​
 

To request other/additional Agency policies, please email Compliance@HelmsHomeCare.com

​